Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-GD2-800CW
- Development stage
- Phase 2
- Lead developer
- Princess Máxima Center for Pediatric Oncology
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Anti-GD2-800CW** is an investigational, tumor-targeted near-infrared fluorescence imaging agent being developed by Prinses Máxima Centrum voor Kinderoncologie for use during surgery for pediatric neuroblastoma. It consists of an anti-GD2 monoclonal antibody conjugated to an 800CW near-infrared fluorophore. Following intravenous administration, the agent binds the disialoganglioside GD2 on neuroblastoma cells and enables intraoperative fluorescence visualization of tumor tissue and potentially involved margins or residual disease. It is being evaluated in the first-in-human GLOW-FISH phase Ib/II study for safety, pharmacokinetics, and tumor-specific fluorescence imaging performance rather than as an antitumor therapeutic.
- Other names
- anti-GD2 antibody-IRDye800CW conjugateanti-GD-2 antibody-IRDye800CW conjugateanti-GD 2 antibody-IRDye800CW conjugate
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)GD2C1Q (Complement C1q)
Beyond the preview
Go deeper on Anti-GD2-800CW.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-GD2-800CW.